Clinical oncology is experiencing rapid growth in data that are collected to enhance cancer
care. With recent advances in the field of artificial intelligence (AI), there is now a …

Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Background Risk stratification or progression in prostate cancer is performed with the
support of clinical-pathological data such as the sum of the Gleason score and serum levels …

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …